The Manufacturers Life Insurance Company Sells 313 Shares of Harrow, Inc. (NASDAQ:HROW)

The Manufacturers Life Insurance Company trimmed its position in Harrow, Inc. (NASDAQ:HROW) by 2.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,552 shares of the company’s stock after selling 313 shares during the period. The Manufacturers Life Insurance Company’s holdings in Harrow were worth $519,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. First Turn Management LLC purchased a new stake in shares of Harrow in the third quarter worth $14,683,000. Assenagon Asset Management S.A. purchased a new stake in shares of Harrow in the 3rd quarter valued at about $8,572,000. Charles Schwab Investment Management Inc. boosted its position in shares of Harrow by 195.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after acquiring an additional 166,602 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Harrow during the third quarter worth about $5,864,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Harrow in the second quarter worth approximately $1,698,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Stock Down 2.5 %

Shares of NASDAQ HROW opened at $35.50 on Friday. The stock has a market capitalization of $1.26 billion, a P/E ratio of -37.77 and a beta of 0.69. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a one year low of $9.13 and a one year high of $59.23. The firm’s 50 day simple moving average is $46.12 and its two-hundred day simple moving average is $36.05.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HROW. B. Riley dropped their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. Lake Street Capital lifted their price objective on shares of Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, October 4th. Finally, Craig Hallum increased their target price on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, October 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.